Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Sign up now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/6WMt9CHaMs4.


A stock everyone won't stop talking about is not always a good stock. In fact, these days it's most likely a meme stock which means a bunch of tools think that they can wish their way into a better zip code. HIMS stock doesn't seem to be meme stock, but there are signs it's being pumped on social media. Regardless, we start by looking at how this company makes money. They're basically selling prescriptions online for conditions that bear a stigma. We're told that Hims is expanding into all these other areas, but unless we're provided some granularity on revenue streams, we have no idea what's working and what's not. There are no barriers to entry, and their success so far can be attributed to heavy marketing. How long before pricing pressure affected those margins in the 70s? Revenue growth and gross margins look great, but there's just not enough transparency here around what they're actually selling. Selling curious male boner pills is one thing, but cholesterol drugs? We're not convinced and will be passing on $HIMS stock.

Ver todos los episodios